

Announcement Summary

Entity name PHARMAXIS LTD

Announcement Type

New announcement

Date of this announcement

Wednesday April 14, 2021

The Proposed issue is: ③ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
PXS	ORDINARY FULLY PAID	54,586,141

Proposed +issue date

Wednesday April 21, 2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

PHARMAXIS LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

Solution New announcement

1.5 Date of this announcement

Wednesday April 14, 2021

1.6 The Proposed issue is:

☑ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

🕑 No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Securities class

Will the proposed issue of this +security include an offer of attaching +securities? ℭNo

Details of +securities proposed to be issued

ASX +security code and description

PXS : ORDINARY FULLY PAID

Number of +securities proposed to be issued

54,586,141

Offer price details

In what currency is the cash consideration being paid?

What is the issue price per +security? AUD 0.08000

AUD - Australian Dollar

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes



Part 7C - Timetable

7C.1 Proposed +issue date

Wednesday April 21, 2021

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? ⓒ No

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

54586141

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⓒ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? So

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? ☑ No

Part 7E - Fees and expenses

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% of proceeds



7E.2 Is the proposed issue to be underwritten? $\ensuremath{\mathfrak{C}}$ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

To strengthen the Company's balance sheet, support its clinical program, for general working capital purposes and to pay the costs of the offer

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

no